Session » RA – Diagnosis, Manifestations, & Outcomes Poster III

Date: Monday, November 18, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 2243

A Cross-sectional Study of the Association Between Anxiety State and Various Factors in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2242

A Cross-sectional Study on Predictors of COVID-19 Infection, Admission and Mortality and Effect of Immunomodulating Treatments in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2217

A Significant Alteration in Circulating Endocannabinoid Levels in Rheumatoid Arthritis and Fibromyalgia Syndrome Patients and Its Correlation with Diseases Severity

10:30AM-12:30PM: Abstract Number: 2216

Additive Impact of Rheumatoid Arthritis and HBcAb+ on All-cause and Cardiovascular Mortality

10:30AM-12:30PM: Abstract Number: 2224

Age of Onset of Rheumatoid Arthritis and Radiographic Changes

10:30AM-12:30PM: Abstract Number: 2239

Age, Seropositivity and Inflammation Determine Risk versus Benefit of Endogenous Estrogens on Coronary Atherosclerosis in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2232

Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort

10:30AM-12:30PM: Abstract Number: 2229

Aptamer Based Proteomic Profiling Demonstrates Significant Differences in Methotrexate Responders versus Non-responders in Newly Diagnosed Rheumatoid Arthritis and Adds Potential Value to Clinical Examination

10:30AM-12:30PM: Abstract Number: 2249

Assessment of Interstitial Lung Disease in Rheumatoid Arthritis Patients Treated with JAK Inhibitors: A National Multicenter Observational Study from the MAJIK-SFR Registry

10:30AM-12:30PM: Abstract Number: 2218

Association Between Frailty and Peri-Operative Inpatient Adverse Outcomes Among Patients with and Without Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2221

Association Between Serum Uric Acid/Serum Creatinine Index and Carotid Plaque in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2219

Association of Chondrocalcinosis with Disease Activity and Drug Response in Rheumatoid Arthritis: Baseline Characteristics of the Swiss Rheumatoid Arthritis Outcomes Cohort

10:30AM-12:30PM: Abstract Number: 2248

Association of Integrative Health Practices with Health-Related Quality of Life in Women with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2241

Associations Between Disease Activity, Physical Function and Anti-rheumatic Medications with All-cause Mortality in Rheumatoid Arthritis (RA): Data from a Canadian RA Registry

10:30AM-12:30PM: Abstract Number: 2250

Cause Specific Mortality Differs in Rheumatoid Arthritis by Sex and Seropositivity

10:30AM-12:30PM: Abstract Number: 2245

Clinical Efficacy and Molecular Cardiovascular Changes of Baricitinib in Biologic-naïve Patients with Rheumatoid Arthritis. Direct Comparative Analysis with TNF Inhibitors and Conventional DMARDs

10:30AM-12:30PM: Abstract Number: 2208

Clinical, Imaging and Treatment Characteristics of Patients with Progressive Systemic Autoimmune Rheumatic Disease-related Interstitial Lung Diseases (SARD-ILDs) in the ILD-PRO Registry

10:30AM-12:30PM: Abstract Number: 2210

Comparison of Dual RF and Anti-CCP Seropositive, Single Seropositive, and Seronegative RA on Radiographic Changes, Flares, and Mortality

10:30AM-12:30PM: Abstract Number: 2214

Confirming a Value for Rheumatoid Arthritis Flares Based on Changes in CDAI, SDAI and RAPID3

10:30AM-12:30PM: Abstract Number: 2228

Feasibility, Safety, and Application for Clinical Indication and Research Purposes of Synovial Tissue Analysis in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2211

Identifying Clinical Predictors of Difficult-to-Treat Rheumatoid Arthritis Using Machine Learning-based Techniques

10:30AM-12:30PM: Abstract Number: 2209

Impact of Common Infections on Medication Interruptions, Quality of Life, and Disease Flares in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2233

Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2240

Methotrexate Use Influenced the Effect of Inflammation on Cardiovascular Risk Differently in Anticitrullinated Protein Antibody Negative and Positive Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2213

Microvascular and Macrovascular Endothelial Dysfunction in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2220

Outcomes in Seronegative Rheumatoid Arthritis and Undifferentiated Arthritis

10:30AM-12:30PM: Abstract Number: 2222

Primary Lung Involvement in Early Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2247

Pro-inflammatory Monocytes and CD11c Expression in ACPA Positive Individuals with Arthralgia and Their Associations with Subclinical Synovitis Preceding the Onset of Arthritis

10:30AM-12:30PM: Abstract Number: 2234

Pulmonary Damage Biomarkers and Progression of Rheumatoid Arthritis-associated Interstitial Lung Disease in a Prospective Longitudinal Cohort

10:30AM-12:30PM: Abstract Number: 2236

Relation Between Sociodemographic Factors and Hand Function in Patients with Early Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2230

Relationship Between the Complement System and Serum Lipid Profile in Patients with Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2225

Role of Fatigue in Difficult to Treat Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2246

Safety and Efficacy of Cannabidiol in Rheumatoid Arthritis Patients: A Phase 1B Pilot Randomized Placebo Controlled Trial

10:30AM-12:30PM: Abstract Number: 2212

Seropositive Arthralgias: A Comprehensive Analysis of the Reuma-Check Cohort

10:30AM-12:30PM: Abstract Number: 2226

Site-specific Differences in the Association of Non-vertebral Major Osteoporotic Fractures and Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2251

Stress-Related Neural Activity Measured with FDG-PET/CT Is Associated with Articular Disease Activity, Systemic Inflammation, and Treatment-associated Change in Arterial Inflammation in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2237

The Association Between Bariatric Surgery and Incident Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2238

The Effect of Inflammation on Cardiovascular Risk in Rheumatoid Arthritis Varies According to Sex and Anticitrullinated Protein Antibody Status

10:30AM-12:30PM: Abstract Number: 2235

The Updated PREVENT (Predicting Risk of CVD EVENTs) Algorithm Is Not Able to Indicate Subclinical Coronary or Carotid Atherosclerosis Better Than the Traditional Pooled Cohort Equations in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2215

Treat (Depression to Reach)-to-Target in Rheumatoid Arthritis

10:30AM-12:30PM: Abstract Number: 2231

Treatment Response over the First 6 Months in Newly Diagosed RA Patients by Pain, Anxiety, Depression & Fatigue (PADF) Symptom Clusters: Results from the Canadian Early Arthritis Cohort

10:30AM-12:30PM: Abstract Number: 2244

Unveiling Synovial Protein Contributions to Serum Inflammation, Disease Activity, and Treatment Outcomes in RA Patients

10:30AM-12:30PM: Abstract Number: 2223

Validation Study in Early Rheumatoid Arthritis Patients of the Spanish Society of Rheumatology (SER)/Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) Screening Criteria for Interstitial Lung Disease

10:30AM-12:30PM: Abstract Number: 2227

Worrisome Mortality Trends over 20 Years Among Patients with Underlying Ischemic Heart Disease and Rheumatoid Arthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].